EVKEEZA
PeakmAbBLAINJECTIONSOLUTIONPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
EVKEEZA by Regeneron is evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits angptl3. First approved in 2021.
Drug data last refreshed 12h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EVKEEZA (evinacumab-dgnb) is a recombinant human monoclonal antibody approved in 2021 that inhibits ANGPTL3, a liver-expressed regulator of lipid metabolism. It reduces LDL-cholesterol, HDL-cholesterol, and triglycerides by promoting VLDL clearance and rescuing lipoprotein lipase activity, functioning independently of the LDL receptor. EVKEEZA targets severe dyslipidemia and related lipid disorders.
$0.007BPart D
PeakDrug is at peak lifecycle stage with modest Part D penetration (163 claims in 2023), suggesting established but niche market positioning with stable commercial team demands.
Mechanism of Action
Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Started Jun 2020
20 enrolled
Homozygous Familial Hypercholesterolemia
Career Relevance
Working on EVKEEZA offers exposure to specialty pharmaceutical commercialization, regulatory excellence at Regeneron, and leadership development in a niche but strategically important lipid therapy market. The 545 linked jobs reflect substantial infrastructure supporting a peak-stage biologic with complex manufacturing, reimbursement, and medical education demands.
Worked on EVKEEZA at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.